[go: up one dir, main page]

CL2018001384A1 - Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales - Google Patents

Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales

Info

Publication number
CL2018001384A1
CL2018001384A1 CL2018001384A CL2018001384A CL2018001384A1 CL 2018001384 A1 CL2018001384 A1 CL 2018001384A1 CL 2018001384 A CL2018001384 A CL 2018001384A CL 2018001384 A CL2018001384 A CL 2018001384A CL 2018001384 A1 CL2018001384 A1 CL 2018001384A1
Authority
CL
Chile
Prior art keywords
vinbas
tumor cells
wnt signaling
polypeptides
biparatopic polypeptides
Prior art date
Application number
CL2018001384A
Other languages
English (en)
Inventor
Vittoria Zinzalla
Klaus-Peter Kuenkele
Marie-Ange Buyse
Karen Cromie
Stephanie Staelens
Beatrijs Strubbe
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2018001384A1 publication Critical patent/CL2018001384A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA INVENCIÓN PROPORCIONA POLIPÉPTIDOS DE UNIÓN DE REACCIÓN CRUZADA CON LRP5/LRP6 BIPARATÓPICOS NOVEDOSOS Y, EN PARTICULAR, CONSTRUCCIONES DE DOMINIO VARIABLE ÚNICO DE INMUNOGLOBULINA DE REACCIÓN CRUZADA CON LRP5/LRP6 BIPARATÓPICOS NOVEDOSAS QUE INHIBEN LAS VÍAS DE SEÑALIZACIÓN WNT. LA INVENCIÓN TAMBIÉN SE REFIERE A SECUENCIAS ESPECÍFICAS DE ESTOS POLIPÉPTIDOS, MÉTODOS PARA PREPARARLOS Y MÉTODOS PARA USARLOS, QUE INCLUYEN MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES, TALES COMO CÁNCER.
CL2018001384A 2015-12-04 2018-05-23 Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales CL2018001384A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15197999 2015-12-04

Publications (1)

Publication Number Publication Date
CL2018001384A1 true CL2018001384A1 (es) 2018-09-14

Family

ID=54782606

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001384A CL2018001384A1 (es) 2015-12-04 2018-05-23 Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales

Country Status (34)

Country Link
US (2) US10597449B2 (es)
EP (2) EP3797790A1 (es)
JP (2) JP6728355B2 (es)
KR (1) KR102802241B1 (es)
CN (1) CN108289943B (es)
AR (1) AR106949A1 (es)
AU (1) AU2016363787B2 (es)
BR (1) BR112018010537A2 (es)
CA (1) CA3006235A1 (es)
CL (1) CL2018001384A1 (es)
CO (1) CO2018005680A2 (es)
CY (1) CY1123454T1 (es)
DK (1) DK3383425T3 (es)
EA (1) EA201891331A1 (es)
ES (1) ES2821099T3 (es)
HR (1) HRP20201528T1 (es)
HU (1) HUE051777T2 (es)
IL (1) IL259119B (es)
LT (1) LT3383425T (es)
MA (2) MA54648A (es)
MX (1) MX380414B (es)
MY (1) MY200933A (es)
NZ (1) NZ742037A (es)
PE (1) PE20181515A1 (es)
PH (1) PH12018501155B1 (es)
PL (1) PL3383425T3 (es)
PT (1) PT3383425T (es)
RS (1) RS60823B1 (es)
SA (1) SA518391728B1 (es)
SG (1) SG11201804510PA (es)
SI (1) SI3383425T1 (es)
TW (1) TWI734719B (es)
UA (1) UA122079C2 (es)
WO (1) WO2017093478A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2017120287A (ru) 2012-02-28 2018-11-15 АйАрЭм ЭлЭлСи ОТБОР БОЛЬНЫХ РАКОМ ДЛЯ ВВЕДЕНИЯ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ Wnt НА ОСНОВАНИИ СТАТУСА МУТАЦИИ RNF43
SG10201911035QA (en) 2015-11-18 2020-01-30 Merck Sharp & Dohme Pd1 and/or lag3 binders
MA54648A (fr) * 2015-12-04 2021-11-10 Boehringer Ingelheim Int Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US11033636B2 (en) * 2017-05-31 2021-06-15 Boehringer Ingelheim International Gmbh Polypeptides antagonizing Wnt signaling in tumor cells
JP2020530454A (ja) 2017-08-07 2020-10-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 安全な細胞治療薬を生成するためのプラットフォーム
MX2020005424A (es) 2017-11-29 2020-12-03 Univ Texas Composiciones y metodos para terapia contra el cancer.
US11773171B2 (en) 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
CN120623353A (zh) * 2018-07-05 2025-09-12 瑟罗泽恩奥普瑞汀公司 多特异性wnt替代分子和其用途
WO2020080941A1 (en) * 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
TW202104258A (zh) 2019-03-29 2021-02-01 德商百靈佳殷格翰國際股份有限公司 抗癌組合療法
BR112021016520A2 (pt) 2019-03-29 2021-10-26 Boehringer Ingelheim International Gmbh Terapia de combinação anticâncer
US11434297B2 (en) 2019-05-04 2022-09-06 Inhibrx, Inc. CD123-binding polypeptides and uses thereof
MA55910A (fr) * 2019-05-08 2022-03-16 2Seventy Bio Inc Immunothérapies ciblant cd123
CA3147832A1 (en) * 2019-08-14 2021-02-18 Sachdev S. Sidhu Antibodies that bind to lrp6 proteins and methods of use
CA3147827A1 (en) * 2019-08-14 2021-02-18 Modmab Therapeutics Inc. Antibodies that bind to lrp5 proteins and methods of use
AU2020355027A1 (en) 2019-09-23 2022-04-21 Twist Bioscience Corporation Antibodies that bind CD3 Epsilon
CN112794914B (zh) * 2019-11-14 2022-09-16 深圳华大生命科学研究院 一种基于噬菌体展示技术开发的alk纳米抗体及其应用
WO2021163490A1 (en) * 2020-02-14 2021-08-19 University Of Washington Targeted depletion of bacteria from mixed populations through programmable cell-cell adhesion
US12258406B2 (en) 2021-03-24 2025-03-25 Twist Bioscience Corporation Antibodies that bind CD3 Epsilon
US20240391997A1 (en) * 2021-07-16 2024-11-28 Brightpath Biotherapeutics Co., Ltd. Anti-tim-3 antigen antibody or antibody derivative, and use thereof
WO2024147897A2 (en) * 2023-01-05 2024-07-11 Harpoon Therapeutics, Inc. Trop2 targeting trispecific protein for treatment of cancer
CN116375851B (zh) * 2023-03-03 2024-03-22 中国农业科学院兰州兽医研究所 一种抗禽流感病毒np蛋白的纳米抗体及其制备方法与应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
US6528054B1 (en) 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
CA2484556A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
BRPI0518151A2 (pt) 2004-10-13 2009-06-16 Ablynx Nv polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
CN103254309B (zh) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
US7622267B2 (en) * 2006-05-30 2009-11-24 Van Andel Research Institute Low-density lipoprotein receptor 6 (LRP6) as a mammary stem cell marker and related methods
EP2447558B1 (en) 2006-06-08 2013-05-29 NSK Ltd. Method for manufacturing a drawn cup needle roller bearing having a seal ring
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
CN100428934C (zh) 2006-09-07 2008-10-29 中国人民解放军第二军医大学 香豆素类化合物在制备诱导神经干细胞定向分化药物中的应用
AU2007293614A1 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
JP2010511397A (ja) 2006-12-05 2010-04-15 アブリンクス エン．ヴェー． 血清タンパク質と結合可能なペプチド
ES2560532T3 (es) 2007-11-02 2016-02-19 Novartis Ag Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (LRP6)
CA2717015A1 (en) 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US8661423B2 (en) 2009-05-01 2014-02-25 Telcordia Technologies, Inc. Automated determination of quasi-identifiers using program analysis
US8276148B2 (en) 2009-12-04 2012-09-25 International Business Machines Corporation Continuous optimization of archive management scheduling by use of integrated content-resource analytic model
EP3498731A1 (en) 2009-12-23 2019-06-19 ESBATech, an Alcon Biomedical Research Unit LLC Method for decreasing immunogenicity
WO2011095545A1 (en) 2010-02-05 2011-08-11 Ablynx Nv Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
WO2011107507A1 (en) 2010-03-03 2011-09-09 Boehringer Ingelheim International Gmbh Biparatopic abeta binding polypeptides
SG184033A1 (en) * 2010-03-24 2012-10-30 Genentech Inc Anti-lrp6 antibodies
US9290573B2 (en) * 2010-05-06 2016-03-22 Novartis Ag Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
ES2659406T3 (es) 2010-05-06 2018-03-15 Novartis Ag Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6)
KR20140001216A (ko) * 2010-10-20 2014-01-06 제넨테크, 인크. Wnt 경로를 조절하기 위한 방법 및 조성물
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US8790650B2 (en) * 2011-04-28 2014-07-29 Vanderbilt University Methods of using an antibody to inhibit WNT-mediated cardiac remodeling
NZ780183A (en) 2011-06-23 2024-12-20 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
PE20141522A1 (es) 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
MX2014005411A (es) 2011-11-04 2015-02-12 Novartis Ag Construcciones prolongadas de la vida media de la proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
JP5949270B2 (ja) 2012-07-24 2016-07-06 富士通株式会社 オーディオ復号装置、オーディオ復号方法、オーディオ復号用コンピュータプログラム
EP2888279A1 (en) 2012-08-22 2015-07-01 Glaxo Group Limited Anti lrp6 antibodies
MA54648A (fr) 2015-12-04 2021-11-10 Boehringer Ingelheim Int Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales

Also Published As

Publication number Publication date
DK3383425T3 (da) 2020-09-28
CN108289943B (zh) 2023-06-20
IL259119B (en) 2022-04-01
CN108289943A (zh) 2018-07-17
NZ742037A (en) 2025-07-25
WO2017093478A1 (en) 2017-06-08
TW201731868A (zh) 2017-09-16
JP2019506841A (ja) 2019-03-14
AU2016363787B2 (en) 2023-02-02
MX380414B (es) 2025-03-12
EP3383425A1 (en) 2018-10-10
ES2821099T3 (es) 2021-04-23
EP3797790A1 (en) 2021-03-31
HK1255725A1 (en) 2019-08-23
UA122079C2 (uk) 2020-09-10
SG11201804510PA (en) 2018-06-28
AR106949A1 (es) 2018-03-07
CY1123454T1 (el) 2022-03-24
PT3383425T (pt) 2020-10-07
MY200933A (en) 2024-01-24
PH12018501155B1 (en) 2024-06-28
EP3383425B1 (en) 2020-07-15
US20170174762A1 (en) 2017-06-22
PE20181515A1 (es) 2018-09-21
US20200199222A1 (en) 2020-06-25
PL3383425T3 (pl) 2021-01-11
US10597449B2 (en) 2020-03-24
LT3383425T (lt) 2020-10-12
PH12018501155A1 (en) 2019-01-28
SI3383425T1 (sl) 2020-11-30
BR112018010537A2 (pt) 2018-11-13
MA54648A (fr) 2021-11-10
JP2020178701A (ja) 2020-11-05
EA201891331A1 (ru) 2018-12-28
MA43368B1 (fr) 2020-09-30
IL259119A (en) 2018-06-28
TWI734719B (zh) 2021-08-01
MX2018006760A (es) 2018-08-01
MA43368A (fr) 2018-10-10
US11952418B2 (en) 2024-04-09
CA3006235A1 (en) 2017-06-08
AU2016363787A1 (en) 2018-05-17
KR20180081825A (ko) 2018-07-17
SA518391728B1 (ar) 2022-03-28
KR102802241B1 (ko) 2025-05-07
RS60823B1 (sr) 2020-10-30
JP6728355B2 (ja) 2020-07-22
HRP20201528T1 (hr) 2020-12-11
HUE051777T2 (hu) 2021-03-29
CO2018005680A2 (es) 2018-06-12

Similar Documents

Publication Publication Date Title
CL2018001384A1 (es) Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales
CO2019012329A2 (es) Polipéptidos que antagonizan la señalización wnt en células tumorales
CL2018003153A1 (es) Moléculas de anticuerpo para el tratamiento del cáncer.
ECSP17062716A (es) Heterociclos bicíclicos como inhibidores de fgfr4
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
NI201700042A (es) Composiciones y métodos de uso para tratar trastornos metabólicos.
PE20170441A1 (es) Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
MX381046B (es) Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
UY37018A (es) Inhibidores bicíclicos de pad4
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2017006283A (es) Peptidos macrociclicos utiles como inmunomoduladores.
BR112017006664A2 (pt) terapias de combinação
MX384490B (es) Agentes que inducen apoptosis para el tratamiento de cancer y enfermedades inmunitarias y autoinmunitarias.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2018002810A1 (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.
MX373818B (es) Composiciones de apilimod y métodos para usar las mismas.
PE20151925A1 (es) Anticuerpos anti-igf-1r con abolicion de la union al fcrn y su utilizacion en el tratamiento de enfermedades oculares vasculares
BR112016021066A2 (pt) anticorpos humanizados com estabilidade aumentada
MX2016015163A (es) Biomarcadores mit y metodos para su uso.
MX391474B (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis
MX378112B (es) Anticuerpos que potencian el factor h y sus usos.
UY36086A (es) Compuestos de quinoxalina y usos de los mismos